Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Comment by steelinvestoron Feb 01, 2017 2:37pm
160 Views
Post# 25784841

RE:RE:RE:FDA

RE:RE:RE:FDAI have a large position and continue to accumulate on the pullbacks (if there is a spike, I sell some into it, although its just to offset costs on my buys) My analysis is that  A) FDA on efficacy will be approved - based on all the positive data being published (whitepapers) and its non-invasiveness 
B) They will own and lead a very large, untapped market worth multiple billions per annum C) the company's market cap is under $200MM - cheap in this space, so close to FDA approval
D) US military's $37MM collaboration - end result will be a large order upon FDA approval.
As this company nears the FDA approval timeline, the stock tightens and goes up in value. That is why it's now trading over the $2 range. With approx 80MM shares out (fully diluted) there is not a lot of volume, yet the stock is firm. This tells me there is a strong "wait for FDA" sentiment out there because of the massive upside on value.
Bullboard Posts